40.41
Precedente Chiudi:
$49.56
Aprire:
$44.25
Volume 24 ore:
316.93K
Relative Volume:
8.09
Capitalizzazione di mercato:
$3.07B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+39.68%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Jyong Biotech Ltd Stock (MENS) Company Profile
Nome
Jyong Biotech Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta MENS con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
MENS
Jyong Biotech Ltd
|
40.41 | 3.77B | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Jyong Biotech Ltd Borsa (MENS) Ultime notizie
Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain - Seeking Alpha
Jyong Biotech Ltd.'s Quiet Period Will End on July 28th (NASDAQ:MENS) - MarketBeat
Jyong Biotech Ltd. Completes Nasdaq IPO and Showcases MCS®-2 at BIO 2025 International Convention - Nasdaq
Jyong Biotech Completes Nasdaq IPO, Participates in BIO 2025 Convention. - AInvest
Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention - GlobeNewswire
Taiwan's Jyong Biotech Takes On $9.8B BPH Market With Revolutionary Plant-Based Treatment After Nasdaq IPO - Stock Titan
Jyong Biotech Ltd.’s Quiet Period Set To Expire on July 28th (NASDAQ:MENS) - Defense World
Biopharma financings total $28.7B in H1, down 59% from 2024 - BioWorld MedTech
Jyong Biotech shares fall 3.33% in premarket after Wall Street Zen upgrades rating to 'hold'. - AInvest
Yong Biotech Ltd (Nasdaq:MENS) Marks Milestone at Nasdaq Composite MarketSite - Kalkine Media
Jyong Biotech shares fall 3.12% in after-hours after Wall Street Zen upgrades rating to 'hold' and CEO rings closing bell at Nasdaq. - AInvest
Pre-market Movers: BGLC, ATAI, GOVX, SNGX... - RTTNews
Jyong Biotech shares fall 4.92% in after-hours following a 34.80% surge post-Nasdaq listing and 11.04% gain over the past five days. - AInvest
Jyong Biotech shares rise 2.11% intraday as biotech sector gains and company completes $20M IPO. - AInvest
Jyong Biotech shares rise 11.82% intraday after successful $20 million IPO and addition to Nasdaq Composite Index. - AInvest
Jyong’s $20M US IPO to help refile NDA of urological botanic drug - BioWorld MedTech
Jyong Biotech Soars 11.13% Post $20M IPO - AInvest
MENSJyong Biotech Ltd. Latest Stock News & Market Updates - Stock Titan
Jyong Biotech Plunges 10.98% Despite IPO Surge - AInvest
Taiwan’s Jyong Biotech doubles in value on Nasdaq debut - Investing.com
Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering - GlobeNewswire
Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle (MENS) - Seeking Alpha
MENS IPO NewsUrinary disease biotech Jyong Biotech sets terms for $19 million US IPO - renaissancecapital.com
Commercial-ready Taiwanese biotech developing therapies for urinary diseases. - renaissancecapital.com
JYB IPO NewsUrinary disease biotech Jyong Biotech withdraws $40 million US IPO - renaissancecapital.com
Jyong Biotech Ltd. Begins U.S. IPO Rollout (Pending:JYB) - Seeking Alpha
Laxton Investments Company Ltd. v. Jyong Biotech Ltd. et al: Originating Summons - OffshoreAlert
Markets Today — Quotes, Charts, and Events - TradingView
Jyong Biotech Ltd Azioni (MENS) Dati Finanziari
Non sono disponibili dati finanziari per Jyong Biotech Ltd (MENS). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):